<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857346</url>
  </required_header>
  <id_info>
    <org_study_id>KSU334</org_study_id>
    <nct_id>NCT04857346</nct_id>
  </id_info>
  <brief_title>Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus</brief_title>
  <official_title>Indocyanine-mediated Antimicrobial Photodynamic Therapy Promotes Superior Clinical Effects in Stage III and Grade C Chronic Periodontitis Among Different Forms of Diabetes Mellitus: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this design, this study hypothesizes that; (i) ICG-PDT would produce superior clinical,&#xD;
      microbiological, and immune-inflammatory outcomes as compared to RSD and (ii) ICG-PDT would&#xD;
      produce equal efficacy among different forms of diabetes as produced in non-diabetic subjects&#xD;
      and that diabetes mellitus would not produce negative impact on the therapeutic outcomes of&#xD;
      ICG-PDT. Therefore, the aim of this randomized controlled clinical trial was to evaluate the&#xD;
      efficacy of ICG-mediated aPDT in the treatment of stage III grade C periodontitis among&#xD;
      patients with prediabetes, T2DM and non-diabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 12, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probing depth</measure>
    <time_frame>6 months</time_frame>
    <description>Probing depth will be measured to the nearest millimeter from the base of the periodontal pocket to the crest of the marginal gingiva.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical attachment level will be measured by adding recession with probing depth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plaque scores</measure>
    <time_frame>6 months</time_frame>
    <description>Dichotomous scoring to each site of the tooth as '1 - present' and '0 - absent'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding on probing</measure>
    <time_frame>6 months</time_frame>
    <description>Dichotomous scoring to each site of the tooth as '1 - present' and '0 - absent'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Porphyromonas gingivalis</measure>
    <time_frame>6 months</time_frame>
    <description>Presence or absence of bacteria from the plaque biofilms in the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>6 months</time_frame>
    <description>Proinflammatory cytokine levels that will be quantified in the laboratory.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Prediabetic State</condition>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Controlled Type 2 diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncontrolled Type 2 diabetes melltius</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.</description>
    <arm_group_label>Controlled Type 2 diabetes mellitus</arm_group_label>
    <arm_group_label>Non-diabetic patients</arm_group_label>
    <arm_group_label>Uncontrolled Type 2 diabetes melltius</arm_group_label>
    <other_name>Photodynamic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged ≥30 years&#xD;
&#xD;
          2. clinically diagnosed with mild to moderate periodontitis&#xD;
&#xD;
          3. self-reported type-2 DM for ≥2 years confirmed by a physician with HbA1c levels ≥6.5%&#xD;
&#xD;
          4. patients who complied with the treatment protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (i) pregnancy and lactation (ii) who had taken antibiotics in the previous 3 months (iii)&#xD;
        who had undergone periodontal therapy or any decontamination treatment in their oral cavity&#xD;
        in the previous 6 months (iv) former/current smokers (v) failure to provide a signed&#xD;
        informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>College of Applied Medical Sciences, King Saud University</name>
      <address>
        <city>Riyadh</city>
        <zip>11454</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Mohammed Mahmoud Al-Momani</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

